The emerging psychedelics industry is expanding rapidly across the globe. With research demonstrating promising therapeutic potential for substances like psilocybin and MDMA to treat mental health conditions, this sector has…
Read More
Biotechnology company Enveric Biosciences has selected EB-003 as its lead drug candidate from its EVM301 series for difficult-to-treat mental health disorders. EB-003 was selected by the company based on data…
Read More
A conversation with Enveric Biosciences CEO Joseph Tucker, Ph.D. Two themes have arisen as of late in the clinical trials space, and both collide in this Q&A for an interesting…
Read More
The non-partisan Digital Politics Podcast with Karen Jagoda highlights the impact of new technologies on the campaign landscape, how expectations of voters are changing, role of online fundraising, digital and…
In this episode of The Mindfulness Experience Podcast, host Keith Fiveson interviews Dr. Joseph Tucker, the CEO and Director of Enveric Biosciences. Enveric Biosciences is a biotechnology company that is…
Read More
Enveric Biosciences has received a Notice of Allowance (NoA) from the United States Patent and Trademark Office (USPTO) for a patent application involving EB-373, the company’s new chemical entity (NCE)…
Read More
Expands its intellectual property portfolio with composition of matter claims governing lead clinical candidate, EB-373, a psilocin prodrug being developed for the treatment of depression and anxiety disorders. CAMBRIDGE, Mass.…
Read More
CEO Joseph Tucker, Ph.D., to deliver company presentation and participate in panel discussion CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the…
Read More
But perhaps, most importantly, says Kevin Coveney, CFO at Enveric Biosciences, is that the CFO needs to understand their role as a support to the CEO in realising their plans.…
Read More
Key preclinical milestone designed to establish safety profile and maximum tolerated dose for anticipated clinical trial of EB-373 CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a…
Read More
